| Authors: |
Hantel A; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA; Center for Bioethics, Harvard Medical School, Boston, MA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA. andrew_hantel@dfci.harvard.edu., Luskin MR; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Khan I; Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Warner E; Center for Bioethics, Harvard Medical School, Boston, MA., Patel AA; Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL., Walsh TP; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA., DeAngelo DJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA., Lathan CS; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA., Abel GA; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA; Center for Bioethics, Harvard Medical School, Boston, MA; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA. |
